STOCKHOLM, Feb. 5, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi ®) today announced its report for the fourth quarter 2024. Total revenue increased 9 per cent, 8 per cent at ...

The strategic portfolio includes Sobi's medicines Altuvoct, Aspaveli/Empaveli, Doptelet, Gamifant ®, Vonjo and Zynlonta ®, and royalty on Sanofi's sales of Altuviiio ® and Beyfortus.

STOCKHOLM, Feb. 5, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi ®) today announced its report for the fourth quarter 2024. Total revenue increased 9 per cent, 8 per cent at constant ...

Lantus sales rose 63.4% to €439.0 million. SNY & AZN’s Beyfortus Drives Vaccine Sales Total vaccine sales increased 10.8% to €2.2 billion, driven by Beyfortus sales in Europe. Sales of flu ...

While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden child could be emerging in the form of Beyfortus. During its first ...

The beyfortus market size is expected to see XX (FCAGR) in the next few years. It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX ...

Starting in November 2024, all babies were able to get the Beyfortus immunization for free through their public health unit, health care provider or hospital. RSV is a common respiratory virus that ...

Nirsevimab is made by AstraZeneca and distributed in Canada by Sanofi, under the name Beyfortus. The single injection protects infants through the fall and winter when RSV circulates regularly.